亚虹医药-U
(688176)
| 流通市值：77.07亿 | | | 总市值：77.07亿 |
| 流通股本：5.72亿 | | | 总股本：5.72亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 155,353,308.79 | 71,085,894.94 | 277,121,519.19 | 216,408,302.14 |
| 营业总成本 | 411,108,158.28 | 189,734,751.55 | 726,362,997.2 | 492,121,292.52 |
| 其他经营收益 | | | | |
| 营业利润 | -242,674,111.25 | -112,359,970.17 | -428,326,573.36 | -258,185,335.83 |
| 利润总额 | -244,770,829.97 | -114,384,224.42 | -433,405,537.09 | -261,643,797.65 |
| 净利润 | -244,943,112.04 | -114,495,059.33 | -432,745,046.85 | -261,050,841.03 |
| 每股收益 | | | | |
| 其他综合收益 | -1,073,071.36 | 1,173,877.89 | -1,487,000.35 | 244,644.07 |
| 综合收益总额 | -246,016,183.4 | -113,321,181.44 | -434,232,047.2 | -260,806,196.96 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 1,575,776,550.31 | 1,635,087,629.97 | 1,761,747,845.08 | 1,831,875,409.94 |
| 非流动资产: | | | | |
| 非流动资产合计 | 271,165,975.71 | 360,089,026.45 | 295,744,968.14 | 316,824,572.54 |
| 资产总计 | 1,846,942,526.02 | 1,995,176,656.42 | 2,057,492,813.22 | 2,148,699,982.48 |
| 流动负债: | | | | |
| 流动负债合计 | 244,190,082.77 | 401,380,914.21 | 402,396,549.09 | 367,297,502.27 |
| 非流动负债: | | | | |
| 非流动负债合计 | 268,819,382.16 | 142,486,244.73 | 92,040,464.61 | 45,195,805.98 |
| 负债合计 | 513,009,464.93 | 543,867,158.94 | 494,437,013.7 | 412,493,308.25 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 1,353,914,703.22 | 1,466,747,909.33 | 1,576,339,574.94 | 1,744,502,159.34 |
| 股东权益合计 | 1,333,933,061.09 | 1,451,309,497.48 | 1,563,055,799.52 | 1,736,206,674.23 |
| 负债和股东权益合计 | 1,846,942,526.02 | 1,995,176,656.42 | 2,057,492,813.22 | 2,148,699,982.48 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 128,825,509.89 | 74,577,942.28 | 280,533,929.51 | 216,356,522.64 |
| 经营活动现金流出小计 | 429,703,016.3 | 199,082,409.29 | 692,327,604.31 | 518,155,423.76 |
| 经营活动产生的现金流量净额 | -300,877,506.41 | -124,504,467.01 | -411,793,674.8 | -301,798,901.12 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 1,308,074,462.21 | 480,925,754.39 | 1,690,865,081.84 | 4,558,419,963.77 |
| 投资活动现金流出小计 | 1,280,075,030.71 | 448,726,247.34 | 1,653,244,958.39 | 4,618,713,630.26 |
| 投资活动产生的现金流量净额 | 27,999,431.5 | 32,199,507.05 | 37,620,123.45 | -60,293,666.49 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 262,948,814.99 | 106,790,000 | 296,119,431.84 | 239,359,346.39 |
| 筹资活动现金流出小计 | 216,612,129.64 | 95,088,310.35 | 89,956,151.13 | 58,270,569.81 |
| 筹资活动产生的现金流量净额 | 46,336,685.35 | 11,701,689.65 | 206,163,280.71 | 181,088,776.58 |
| 汇率变动对现金及现金等价物的影响 | 37,083.01 | -350,302.24 | -1,679,325.05 | -385,166.51 |
| 现金及现金等价物净增加额 | -226,504,306.55 | -80,953,572.55 | -169,689,595.69 | -181,388,957.54 |
| 期末现金及现金等价物余额 | 224,441,063.87 | 369,991,797.87 | 450,945,370.42 | 439,246,008.57 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | -226,504,306.55 | - | -169,689,595.69 | - |